Trial in Progress: A Phase 1-2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients with Advanced Solid Tumors

James Vasselli, Paul de Souza, Sophia Frentzas, Andrew Weickhardt, Timothy Wyant, Jenny Tang, Aron Knickerbocker, Inbar Amit, Yanay Ofran

Research output: Contribution to conferenceAbstractpeer-review

Original languageEnglish
Number of pages1
StatePublished - 3 Jun 2022
Event American Society of Clinical Oncology (ASCO) Annual Meeting -
Duration: 3 Jun 20227 Jun 2022

Conference

Conference American Society of Clinical Oncology (ASCO) Annual Meeting
Period3/06/227/06/22

Cite this